Recruiting PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05958121

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Sponsor: Immatics Biotechnologies GmbH

Conditions Cancer Recurrent Cancer Refractory Cancer Solid Tumor, Adult

Interventions IMA402 (Phase II) IMA402 (Phase Ia) IMA402 (Phase Ib)

Updated 18 times since 2023 Last updated: Nov 17, 2025 Started: Aug 9, 2023 Primary completion: Sep 30, 2027 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cancer and Recurrent Cancer, this trial is actively recruiting participants. The trial is conducted by Immatics Biotechnologies GmbH and has accumulated 18 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

18 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Feb 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 13 earlier versions

Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Jan 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2023 — Sep 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immatics Biotechnologies GmbH

Data source: Immatics Biotechnologies GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Bonn, Germany , Buxtehude, Germany , Chemnitz, Germany , Dresden, Germany , Düsseldorf, Germany , Erlangen, Germany , Essen, Germany , Giessen, Germany , Groningen, Netherlands and 13 more locations